Exicure's Equity Gambit: A Biotech's Risky Play to Survive and Pivot

WILMINGTON, Del. – August 03, 2026 – In the high-stakes world of biotechnology, cash is king. But what happens when the coffers are nearly empty? Exicure, Inc. provided a stark answer today, announcing it will settle a $1.0 million milestone payment not with cash, but with company stock. The move, while preserving precious liquidity, lays bare the precarious financial tightrope the company walks as it attempts a radical strategic pivot.

Exicure will issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. to satisfy the obligation, which was triggered by a significant clinical achievement: the completion of a Phase 2 trial for its lead drug candidate, Burixafor. This transaction is a microcosm of the modern biotech dilemma: celebrating scientific progress while grappling with financial desperation. It's a calculated gamble designed to keep the lights on long enough for a potential breakthrough to materialize, but it comes at the cost of diluting the very shareholders the company aims to reward.

A Necessary Evil to Preserve Cash

To understand this decision, one need only look at Exicure's balance sheet. The company is operating on financial fumes. As of its last quarterly report on March 31, 2026, Exicure held just $2.6 million in cash and cash equivalents. With a net loss of $1.8 million in that same quarter and a history of negative cash flow, a $1 million cash payment represents a potentially catastrophic outflow.

Management's own filings have acknowledged "substantial doubt" about the company's ability to continue as a "going concern," a formal warning that its survival is at risk. In this context, the statement from CEO Jung Soo Kim that settling the payment with stock will "preserve cash and maintain financial flexibility" is a profound understatement. It is a move born of necessity.

For existing shareholders, the cost is a dilution of their ownership, calculated at approximately 2.7%. While that percentage may seem modest in isolation, it's another cut in a long series of them for investors who have seen the stock's value plummet by over 74% in the last 52 weeks. The terms of the deal further illustrate the company's volatile situation. The shares are being issued at a deemed value of $5.81, a price based on prior trading data. This is starkly different from its recent closing price of $1.68 on July 17, 2026, highlighting a negotiation likely based on a more optimistic, and now distant, valuation period. This structure ensures GPCR Therapeutics receives its full $1 million in value, while Exicure avoids a critical cash drain.

The company’s ownership is already heavily concentrated. HiTron Systems Inc. became the majority shareholder in late 2024, wielding significant influence over its strategic direction. Such financial maneuvers, while essential for survival, often occur under the guidance of key stakeholders focused on bridging the company to its next potential value inflection point.

Betting the Farm on Burixafor

This story of financial maneuvering is inextricably linked to one of scientific hope. The milestone payment itself is a testament to genuine progress. Exicure is a company in the midst of a complete transformation. After its original platform in nucleic acid therapies faltered, leading to a major restructuring and the suspension of R&D activities in 2022, the company made a hard pivot.

In January 2025, it acquired GPCR Therapeutics USA Inc., and with it, a new focus on hematologic diseases. The centerpiece of this acquisition is Burixafor (GPC-100), the very drug that triggered this milestone. Burixafor is being developed to improve stem cell mobilization for patients with diseases like multiple myeloma and sickle cell disease, a critical support function for cell and gene therapies.

The completion of a Phase 2 trial and the submission of a Clinical Study Report to the FDA are not trivial accomplishments. They represent years of research and significant capital investment, signaling that the drug has shown enough promise to advance. Further bolstering this optimism, Exicure recently announced the publication of positive Burixafor data in the peer-reviewed Annals of Hematology. The study highlighted the drug's ability to achieve rapid stem cell mobilization in cancer patients, a key marker of its potential efficacy.

Seen through this lens, the equity issuance is a strategic defense of this newfound asset. Exicure is effectively using its own stock as a shield to protect its most promising program, buying crucial time and conserving capital to fund its continued development. The company is betting that the future value of Burixafor will far exceed the present-day cost of dilution.

Equity for Milestones: A Sign of the Times

Exicure's situation is not unique. It exemplifies a broader trend within the biotech industry, particularly among early-stage and cash-strapped firms. In a challenging funding environment where venture capital is more selective and public markets are wary, companies are increasingly turning to creative, non-cash solutions to meet their obligations.

Using equity to settle milestone payments is becoming a common tactic. For the company paying, it is a lifeline that avoids depleting its operational runway. For the recipient, it is a calculated risk. Accepting equity in a financially distressed partner is often preferable to forcing them toward insolvency, where the milestone payment might never be collected at all. It transforms a creditor into a stakeholder, aligning interests toward a shared goal of long-term success.

This trend is a barometer of the biotech capital markets. It signals an environment where survival depends on flexibility and partnership, forcing companies to leverage every available asset—including their own stock—to bridge the long and expensive journey from the lab to the patient.

Navigating a Treacherous Path

For Exicure, the path forward remains fraught with peril. The company is actively "exploring strategic alternatives," corporate language for seeking a merger, acquisition, asset sale, or another transformative deal to secure its future. Its history with Nasdaq, which includes deficiency notices for delayed SEC filings and struggles to meet minimum listing requirements, adds another layer of regulatory risk to its financial instability.

Every corporate action, including the routine "Listing of Additional Shares Notification" filed for this transaction, is performed under a microscope. The company's survival hinges on its ability to flawlessly execute its financial and regulatory obligations while simultaneously advancing its science. This equity issuance is not a solution, but rather one more move in a complex and high-stakes game. Exicure is betting that by conserving cash today, it can live to fight for Burixafor's success tomorrow, hoping that its scientific promise will ultimately triumph over its financial precarity.